EPOCH 21: BIOTECH MARKET RESEARCH $OLMA

Olema Oncology

Mark your calendars - Olema Oncology will share new clinical data from the company’s ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 2024.  Options pricing suggest 65% volatility!  

Be sure to read through to the end for a special update on how much biotech stocks move on approval announcements.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: Data from Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in ER+, HER2-, advanced and/or metastatic breast cancer

DATE: May 16, 2024

IMPLIED VOLATILITY: +/- 65%

BACKGROUND: